Clinical trial
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating…
NCT00357903 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00357903 |
|---|---|
| Title | Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials |
| Official title | Open-Label Extension Treatment With Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) for Participating Patients in Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) Clinical Trials |
| Lead sponsor | Amgen, Industry |
| Collaborators | Immunex Corporation Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Biological |
| Interventions | Etanercept |
| Enrollment | 639 |
| Start date | Apr 1, 1997 |
| Primary completion | Dec 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Jul 28, 2006 |
| Last update posted | Feb 9, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: